AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9849834 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination (SDD) with triple therapy of colimycin, tobramycin, and nystatin administered orally or via nasogastric tube every 6 hours, plus oropharyngeal decontamination with hexitidine for patients with mechanical ventilation or immune-depression.
Number of subjects: 244
Study 9849834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SDD treatment)
Number of subjects: 244
Study 8044943 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue-type plasminogen activator (rTPA) therapy
Number of subjects: 310
Study 8044943 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 310
Study 2566536 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg loratadine
Number of subjects: 41
Study 2566536 — intervention group
Group type: COMPARATOR
Intervention: 120 mg terfenadine
Number of subjects: 41
Study 4586043 — intervention group
Group type: EXPERIMENTAL
Intervention: Millipore filter unit
Number of subjects: 0
Study 30571923 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized rehabilitation therapy
Number of subjects: 260
Study 28867601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine
Number of subjects: 60
Study 28867601 — intervention group
Group type: COMPARATOR
Intervention: Oral nifedipine
Number of subjects: 60
Study 25811889 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (control arm)
Number of subjects: 194
Study 23443650 — intervention group
Group type: EXPERIMENTAL
Intervention: Size selected by matching O-C with SLIPA™ chamber length (Group A, n = 50)
Number of subjects: 100
Study 23443650 — intervention group
Group type: COMPARATOR
Intervention: Size selected by matching the width of the thyroid cartilage with the widest dimension of the SLIPA™ (Group B, n = 50)
Number of subjects: 100
Study 23443650 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 100
Study 21477197 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-verbal reasoning training (15 min/day for 25 days)
Number of subjects: 101
Study 21477197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination training (non-verbal reasoning + working memory)
Number of subjects: 101
Study 21477197 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 101
Study 21477197 — intervention group
Group type: COMPARATOR
Intervention: Placebo version of the combined training
Number of subjects: 101
Study 18959646 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 58
Study 18959646 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 58
Study 17065896 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 46
Study 12581938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral stress management (CBSM) program
Number of subjects: 0
Study 12581938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11938856 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPS plus Gandou tablet
Number of subjects: 146
Study 11938856 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPS
Number of subjects: 146
Study 11938856 — intervention group
Group type: COMPARATOR
Intervention: EDTA
Number of subjects: 146
Study 9171689 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners in Patient Care delivery model (PIPC)
Number of subjects: 2
Study 9171689 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 2
Study 8137583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal distribution imaging (IDI) using 1000 ml of normal saline and 1 mCi of Tc‐99m SC
Number of subjects: 8
Study 8137583 — intervention group
Group type: COMPARATOR
Intervention: Low volumes of saline for IDI
Number of subjects: 8
Study 2461401 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin test reagents from two companies
Number of subjects: 87
Study 2461401 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin test reagents from all companies
Number of subjects: 87
Study 31985725 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 20
Study 31985725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30829771 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 64 U (FHL 20 U, GL 20 U, CFL 24 U)
Number of subjects: 787
Study 30829771 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 40 U (FHL 20 U, GL 20 U, CFL placebo)
Number of subjects: 787
Study 30829771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787
Study 30829771 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (both dosages)
Number of subjects: 787
Study 30829771 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated onabotulinumtoxinA 64 U treatment in Period 2
Number of subjects: 787
Study 30643391 — intervention group
Group type: EXPERIMENTAL
Intervention: Quesero XR 200 mg
Number of subjects: 20
Study 30643391 — intervention group
Group type: COMPARATOR
Intervention: Seroquel XR 200 mg
Number of subjects: 20
Study 30643391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state
Number of subjects: 20
Study 28366518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation with corifollitropin alfa
Number of subjects: 0
Study 28366518 — intervention group
Group type: COMPARATOR
Intervention: Conventional daily gonadotropins (recombinant FSH and highly purified human menopausal gonadotrophin)
Number of subjects: 0
Study 24243931 — intervention group
Group type: COMPARATOR
Intervention: Room temperature tumescence anesthesia (+24℃)
Number of subjects: 101
Study 24243931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold tumescence anesthesia (+4℃)
Number of subjects: 101
Study 24042190 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered self-expandable metal stents (SEMSs)
Number of subjects: 120
Study 24042190 — intervention group
Group type: COMPARATOR
Intervention: Uncovered self-expandable metal stents (SEMSs)
Number of subjects: 120
Study 21585690 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aids for mastectomy versus breast-conserving therapy
Number of subjects: 0
Study 21585690 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aids for axillary dissection versus sentinel node biopsy
Number of subjects: 0
Study 21585690 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 0
Study 19450071 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation treatment schedules
Number of subjects: 187
Study 19450071 — intervention group
Group type: COMPARATOR
Intervention: Medicare patients
Number of subjects: 187
Study 19450071 — intervention group
Group type: COMPARATOR
Intervention: Non-Medicare patients
Number of subjects: 187
Study 17008803 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with twice-daily IFN-beta (3X2=6 million units/day)
Number of subjects: 28
Study 17008803 — intervention group
Group type: COMPARATOR
Intervention: Consensus interferon monotherapy
Number of subjects: 28
Study 17008803 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with twice-daily IFN-beta
Number of subjects: 28
Study 12933575 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m2 with induction chemotherapy (DAT, DA, or FLAG-Ida)
Number of subjects: 72
Study 12933575 — intervention group
Group type: EXPERIMENTAL
Intervention: DA or FLAG-Ida with GO in induction
Number of subjects: 72
Study 12933575 — intervention group
Group type: EXPERIMENTAL
Intervention: GO 3 mg/m2 with consolidation (MACE or HidAC)
Number of subjects: 72
Study 12933575 — intervention group
Group type: COMPARATOR
Intervention: Thioguanine-containing schedules
Number of subjects: 72
Study 10833803 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg
Number of subjects: 10
Study 10833803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9120460 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic inflammatory demyelinating polyneuropathy
Number of subjects: 32
Study 9120460 — intervention group
Group type: EXPERIMENTAL
Intervention: Hereditary motor sensory neuropathy type I
Number of subjects: 32
Study 9120460 — intervention group
Group type: COMPARATOR
Intervention: Guillain‐Barre syndrome
Number of subjects: 32
Study 1551155 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 3.5% in humidified oxygen
Number of subjects: 40
Study 1551155 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 5% in humidified oxygen
Number of subjects: 40
Study 3901465 — intervention group
Group type: EXPERIMENTAL
Intervention: Examinations by different technologists
Number of subjects: 48
Study 3901465 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtaining the velocity waveforms
Number of subjects: 48
Study 3901465 — intervention group
Group type: EXPERIMENTAL
Intervention: Classifying the extent of carotid disease
Number of subjects: 48
Study 3901465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver variability in rereading spectral waveforms
Number of subjects: 48
Study 31628791 — intervention group
Group type: EXPERIMENTAL
Intervention: eMBCT
Number of subjects: 245
Study 31628791 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCT
Number of subjects: 245
Study 30167646 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter interatrial shunt device (IASD; Corvia Medical)
Number of subjects: 43
Study 30167646 — intervention group
Group type: COMPARATOR
Intervention: Sham control treatment
Number of subjects: 43
Study 26975225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy
Number of subjects: 1059
Study 26975225 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy
Number of subjects: 1059
Study 23830769 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiologic tape (KT) applied postoperatively for at least 5 days
Number of subjects: 30
Study 23830769 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiologic tape (KT)
Number of subjects: 30
Study 23830769 — intervention group
Group type: COMPARATOR
Intervention: No kinesiologic tape (control)
Number of subjects: 30
Study 21351291 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple treatments including Chinese herbs, acupuncture, and massage therapy
Number of subjects: 0
Study 21351291 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity score regression adjustment
Number of subjects: 0
Study 21351291 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity score weighting
Number of subjects: 0
Study 20212271 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-based blood pressure-lowering therapy
Number of subjects: 6105
Study 20212271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study 17564952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 80
Study 17564952 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 15735660 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) from a sibling donor in second complete remission
Number of subjects: 92
Study 15735660 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT3 internal tandem duplication (ITD) assessment
Number of subjects: 92
Study 15735660 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor availability
Number of subjects: 92
Study 12233895 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy (omeprazole 20 mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid for 7 days)
Number of subjects: 919
Study 12233895 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone (20 mg once daily)
Number of subjects: 919
Study 12233895 — intervention group
Group type: COMPARATOR
Intervention: H. pylori negative patients (omeprazole 20 mg once daily)
Number of subjects: 919
Study 10081035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily for 2 weeks)
Number of subjects: 13
Study 7752627 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol session (0.625 g/kg body weight of 80-proof ethyl alcohol)
Number of subjects: 10
Study 7752627 — intervention group
Group type: COMPARATOR
Intervention: Placebo session
Number of subjects: 10
Study 2268634 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of fluoride varnish (Duraphat) on cavity walls
Number of subjects: 191
Study 2268634 — intervention group
Group type: COMPARATOR
Intervention: Untreated restorations
Number of subjects: 191
Study 6780021 — intervention group
Group type: EXPERIMENTAL
Intervention: Real bilateral electric convulsion therapy
Number of subjects: 22
Study 6780021 — intervention group
Group type: COMPARATOR
Intervention: Simulated bilateral electric convulsion therapy
Number of subjects: 22
Study 6780021 — intervention group
Group type: EXPERIMENTAL
Intervention: Real bilateral electric convulsion therapy after switching from simulated treatment
Number of subjects: 22
Study 31815655 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese pediatric Tuina (15-25 min treatment once per day for 3 consecutive days)
Number of subjects: 122
Study 31815655 — intervention group
Group type: COMPARATOR
Intervention: Sham pediatric Tuina (15-25 min treatment once per day for 3 consecutive days)
Number of subjects: 122
Study 31815655 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese pediatric Tuina
Number of subjects: 122
Study 31815655 — intervention group
Group type: COMPARATOR
Intervention: Sham pediatric Tuina
Number of subjects: 122
Study 28209636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet (target <2 g sodium per day)
Number of subjects: 58
Study 28209636 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 58
Study 26513032 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Babies Healthy Moms (HBHM)
Number of subjects: 83
Study 26513032 — intervention group
Group type: COMPARATOR
Intervention: Baby Basics (BB)
Number of subjects: 83
Study 23863676 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy
Number of subjects: 152
Study 22691430 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP₅-IPV-Hib vaccine
Number of subjects: 0
Study 22691430 — intervention group
Group type: COMPARATOR
Intervention: DTaP₃-HBV-IPV/Hib
Number of subjects: 0
Study 19556533 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment (specifics not provided)
Number of subjects: 972
Study 19556533 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients fulfilling trial enrollment criteria
Number of subjects: 972
Study 19556533 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not fulfilling trial enrollment criteria
Number of subjects: 972
Study 19556533 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-eligible patients
Number of subjects: 972
Study 16999250 — intervention group
Group type: EXPERIMENTAL
Intervention: LACE (Listening and Communication Enhancement) program, received immediately after baseline testing.
Number of subjects: 65
Study 16999250 — intervention group
Group type: COMPARATOR
Intervention: Control group, received no intervention for one month before crossover to LACE.
Number of subjects: 65
Study 15632895 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-Insulin-Potassium (GIK) intravenous infusion for 24 hours
Number of subjects: 20000
Study 15632895 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (Reviparin) injection twice daily for 7 days
Number of subjects: 20000
Study 15632895 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20000
Study 15632895 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection twice daily for 7 days
Number of subjects: 20000
Study 11684928 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+LD
Number of subjects: 6
Study 9299912 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect task with short lag (repeated after a single intervening trial)
Number of subjects: 0
Study 9299912 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect task with long lag (repeated after a mean of 10 trials)
Number of subjects: 0
Study 9299912 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct task with short lag (repeated after a single intervening trial)
Number of subjects: 0
Study 9299912 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct task with long lag (repeated after a mean of 10 trials)
Number of subjects: 0
Study 7524736 — intervention group
Group type: EXPERIMENTAL
Intervention: nIFN alpha (3 MU) intramuscularly three times weekly
Number of subjects: 65
Study 7524736 — intervention group
Group type: EXPERIMENTAL
Intervention: nIFN alpha (3 MU) intramuscularly three times weekly plus 6-methyl-prednisolone (16 mg/d orally on non-IFN days)
Number of subjects: 65
Study 7524736 — intervention group
Group type: COMPARATOR
Intervention: 6-methyl-prednisolone (16 mg/d orally) only
Number of subjects: 65
Study 7524736 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 65
Study 7524736 — intervention group
Group type: EXPERIMENTAL
Intervention: nIFN alpha plus PDN
Number of subjects: 65
Study 7524736 — intervention group
Group type: EXPERIMENTAL
Intervention: nIFN alpha alone
Number of subjects: 65
Study 7524736 — intervention group
Group type: COMPARATOR
Intervention: PDN alone
Number of subjects: 65
Study 3278969 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 75
Study 3278969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31501081 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-only
Number of subjects: 125
Study 31501081 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-video
Number of subjects: 125
Study 31501081 — intervention group
Group type: COMPARATOR
Intervention: Visual-only
Number of subjects: 125
Study 29764380 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis
Number of subjects: 1467
Study 29764380 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1467
Study 29764380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 1467
Study 26831832 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Support Seeking (SSS)
Number of subjects: 165
Study 26831832 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Efficacy Building (SEB)
Number of subjects: 165
Study 26831832 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 165
Study 26831832 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between SSS and SEB
Number of subjects: 165
Study 26044576 — intervention group
Group type: EXPERIMENTAL
Intervention: High traction force MCD (51-100 N)
Number of subjects: 48
Study 26044576 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium traction force MCD (21-50 N)
Number of subjects: 48
Study 26044576 — intervention group
Group type: COMPARATOR
Intervention: Low traction force MCD (0-20 N)
Number of subjects: 48
Study 23582353 — intervention group
Group type: EXPERIMENTAL
Intervention: AREDS formulation (high-dose antioxidants C, E, β-carotene, and zinc)
Number of subjects: 4757
Study 23582353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4757
Study 23582353 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 4757
Study 20570559 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib plus docetaxel
Number of subjects: 1391
Study 20570559 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 1391
Study 20570559 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib plus docetaxel (in women)
Number of subjects: 1391
Study 20570559 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel (in women)
Number of subjects: 1391
Study 18180976 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg monthly oral ibandronate
Number of subjects: 719
Study 18180976 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg monthly oral ibandronate
Number of subjects: 719
Study 18180976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of ibandronate
Number of subjects: 719
Study 16421061 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic programme (experimental group, n = 9)
Number of subjects: 18
Study 16421061 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 18
Study 14624185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 82
Study 14624185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 14624185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline and CBT
Number of subjects: 82
Study 14624185 — intervention group
Group type: COMPARATOR
Intervention: Placebo and CBT
Number of subjects: 82
Study 10831555 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI with husband's spermatozoa
Number of subjects: 0
Study 10831555 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 0
Study 10174220 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic information
Number of subjects: 0
Study 10174220 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of photographic and written information
Number of subjects: 0
Study 10174220 — intervention group
Group type: COMPARATOR
Intervention: Written material alone
Number of subjects: 0
Study 8155112 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct visual intubation
Number of subjects: 157
Study 8155112 — intervention group
Group type: COMPARATOR
Intervention: Intubation aided by a gum elastic bougie
Number of subjects: 157
Study 3034538 — intervention group
Group type: EXPERIMENTAL
Intervention: PDD 10 mg per day X 10, every 3 weeks (hepatic arterial perfusion)
Number of subjects: 82
Study 3034538 — intervention group
Group type: COMPARATOR
Intervention: 5‐Fu 250 mg per day X 4, every week and thio‐tepa (TSPA) 10 mg, twice a week (hepatic arterial perfusion)
Number of subjects: 82
Study 3034538 — intervention group
Group type: EXPERIMENTAL
Intervention: PDD 20 mg per day X 5, every 3 weeks (intravenous chemotherapy)
Number of subjects: 82
Study 3034538 — intervention group
Group type: COMPARATOR
Intervention: 5‐Fu 500 mg and TSPA 10 mg, twice a week (intravenous chemotherapy)
Number of subjects: 82
Study 3034538 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients receiving hepatic arterial perfusion
Number of subjects: 82
Study 3034538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PDD
Number of subjects: 82